financetom
Business
financetom
/
Business
/
Universal Display's Q2 revenue growth beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Universal Display's Q2 revenue growth beats estimates
Jul 31, 2025 1:49 PM

Overview

* Universal Display ( OLED ) Q2 revenue rises 8.4% yr/yr, beating analyst expectations

* Net income for Q2 was $67.3 mln, up from $52.3 mln last year

* Company raises lower end of 2025 revenue guidance to $650 mln-$700 mln

Outlook

* Universal Display ( OLED ) sees 2025 revenue of $650 mln-$700 mln

* Universal Display ( OLED ) expects growth in OLED IT market demand

Result Drivers

* ROYALTY AND LICENSE FEES - Increase driven by changes in customer mix, despite lower unit material volume

* MATERIAL SALES DECLINE - Decrease attributed to changes in customer mix and lower unit material volume for emitter materials

* OLED MARKET EXPANSION - Co sees growth opportunities in OLED IT market, including tablets, laptops, and monitors

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $171.80 $160.80

Revenue mln mln (7

Analysts

)

Q2 Net $67.30

Income mln

Q2 Gross 77.0%

Margin

Q2 $68.50

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the semiconductors peer group is "buy"

* Wall Street's median 12-month price target for Universal Display Corp ( OLED ) is $176.50, about 17% above its July 30 closing price of $146.45

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 27 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China
Pfizer, Astellas' Combination Therapy Application For Bladder Cancer Accepted in China
Mar 28, 2024
02:03 PM EDT, 03/28/2024 (MT Newswires) -- Pfizer ( PFE ) and Astellas Pharma's supplemental biologics license application for enfortumab vedotin in combination with Keytruda for the first-line treatment of advanced bladder cancer has been accepted by the China National Medical Products Administration's Center for Drug Evaluation, Astellas said Thursday. If approved, enfortumab vedotin with Keytruda would be the first...
Quantum eMotion Awarded $1.2 Million NSERC Grant
Quantum eMotion Awarded $1.2 Million NSERC Grant
Mar 28, 2024
02:07 PM EDT, 03/28/2024 (MT Newswires) -- Quantum eMotion Corp. ( QNCCF ) said Thursday that it has received a research grant of $1.2 million, by the Alliance Quantum grants program, overseen by the Natural Sciences and Engineering Research Council of Canada (NSERC). This grant supports the project Quantum random number generation for highly secure cryptography applications, a collaborative initiative...
--Oracle Reportedly Facing Blacklisting by South African Government
--Oracle Reportedly Facing Blacklisting by South African Government
Mar 28, 2024
02:07 PM EDT, 03/28/2024 (MT Newswires) -- Price: 125.98, Change: +0.71, Percent Change: +0.57 ...
Top Midday Gainers
Top Midday Gainers
Mar 28, 2024
02:10 PM EDT, 03/28/2024 (MT Newswires) -- Avalo Therapeutics ( AVTX ) shares skyrocketed amid heavy trading Thursday after the company completed the acquisition of privately held AlmataBio and said late Wednesday it entered into a private placement of preferred stock and warrants for up to $185 million. Shares catapulted 385% as intraday trading volume jumped to over 22 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved